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There is a major need for the development of new technologies that will facilitate the speed of development of 
vaccine and show a very high safety profile. In the last 10 years, we have developed a new toll like receptor 
agonist (TLR) that can trigger innate immunity follow by a strong adaptive immune response. This new agonist 
targets specifically the TLR7/8 in the endosome of the immune cells. It is made of the coat protein (CP) of a 
plant virus self-assembled around an RNA that forms flexuous rod-shape nanoparticles of 15x100nm. The 
highly repetitive and crystalline nature of the nanoparticles are attractive to immune cells leading to its 
internalization into the endosome where the nanoparticles is broken down by the harsh conditions of this 
compartment which liberate the RNA that trigger TLR7/8 to induce innate immunity.  Therefore, we can use 
those nanoparticles as an adjuvant and improve the immune response to an antigen or as an immune modulator 
through the trigger of innate immunity that can induce protection to viral infection or improve the immune 
response to tumour.  Finally, we have showed that we can engineered the nanoparticles into a vaccine platform 
through fusion of B or T cell epitope at its surface and elicits an efficient and protective immune response to the 
fused epitope. We will discuss the advantage of using this platform in vaccine development or cancer 
immunotherapy and show several examples where it has been shoed to be efficient and promising.  
 
